Health Secretary Shares Concerns About Efficacy of Novavax COVID-19 Vaccine After FDA Delay

Robert F. Kennedy Jr. said the vaccine is not effective.
Health Secretary Shares Concerns About Efficacy of Novavax COVID-19 Vaccine After FDA Delay
Health Secretary Robert F. Kennedy Jr. in Washington in an undated file photograph. Kevin Dietsch/Getty Images
Zachary Stieber
Zachary Stieber
Senior Reporter
|Updated:
0:00

Health Secretary Robert F. Kennedy Jr. said in a new interview that Novavax’s COVID-19 vaccine is not effective, his first comments since regulators missed a deadline to approve the shot.

“We’re looking at that vaccine. It is a single antigen vaccine, and for respiratory illnesses, the single antigen vaccines have never worked,” Kennedy told CBS in an interview released on April 9.
Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth